An orally administered sustained release matrix tablets of Losartan potassium using hydrophilic polymers hydroxypropyl methylcellulose (HPMC) with different grads like HPMC K4M, HPMC E10M and HPMC K100M and to optimize using a 3(2) full factorial design, the drug delivery system encounters a wide range of highly variable conditions, such as pH, agitation intensity, and composition of the gastrointestinal fluids as it passes down the G.I tract. Losartan potassium is an angiotensin II receptor antagonist readily absorbed from the GIT that produce more predictable and increased bioavailability of drug. Gastroprotective dosage forms are drug delivery systems which remain in the stomach for an extended period and allow both spatial and time control of drug liberation. These buoyant systems utilize matrices prepared with swellable polymers such as methocel, polysaccharides (e.g., chitosan), and effervescent components, The system is so prepared that upon arrival in the stomach, carbon dioxide is released, causing the formulation to float in the stomach multiple unit floating pills that generate carbon dioxide when ingested, floating mini capsules with a core of sodium bicarbonate, lactose and polyvinylpyrrolidone coated with hydroxypropyl methylcellulose (HPMC). The Formulation of floating tablets of Losartan Potassium with HPMC K4M, HPMC E10M and HPMC K100M and floating systems based on ion exchange resin technology

The oral administration route remains the best choice for drug delivery owing to its safety, patient compliance and capacity
for self-administration. In addition to being the most convenient route of administration, oral delivery has been limited
owing to the numerous barriers present at the gastro-intestinal (GI) tract. The self-emulsifying formulations can be
administered as water-free pre-concentrates those in situ form nanoemulsions in the fluids of the gastrointestinal tract. Selfnano emulsifying drug delivery systems (SNEDDS) are isotropic mixtures of oil, surfactant, co-surfactant and drug that
form fine oil-in-water nanoemulsion when introduced into aqueous phases under gentle agitation

This study aimed to validate a liquid chromatographic technique for bivalirudin hydrochloride. According to the literature review, there are few references to bivalirudin hydrochloride and its contaminants in pharmaceutical dosage forms and UV spectrophotometric determination of bulk and tablet. A spectrophotometric method has been devised to measure bulk and finished bivalirudin medicines. The proposed approach uses UV spectrophotometric absorption as a solvent; UV absorbance is 276 nm. LOD and LQ were 0.5792g/ml and 1.775g/ml. Bivalirudin's calibration curve at 276nm was linear between 2- 20g/ml. After calculating mean percentage recovery, the method's accuracy was 100.7%. Repeatability increased precision. Selective, accurate, precise, and linear over the examined concentration range. The proposed approach is useful for quality control, routine analysis, and determination of bivalirudin in bulk and medicinal dose formalities, inter and intraday fluctuations, and RSD 1%

A comparison was conducted between the control of blood pressure with clinical pharmacy specialists involved and that with conventional physician management. Analyses in this study were conducted using a parallel prospective design. A minimum baseline blood pressure of 140/90 mmHg was required for eligibility, as well as taking a minimum of one antihypertensive medication. Clinical pharmacy specialists provided hypertension management to eligible patients at one medical office (intervention cohort), whereas usual physician-directed care was provided to patients at another comparable medical office (control cohort). A six-month follow-up was used as the primary outcome measures. After clinical pharmacymanaged patients returned to usual care approximately 1.5 years after enrolment, medical records were reviewed for longterm BP control. The baseline cohort differences were adjusted for using multivariate analyses. In the intervention cohort, 101 subjects completed the study, while in the control cohort, 115 subjects completed it. Compared to control subjects (40.7% and 33.3%, respectively), clinical pharmacy-managed subjects had a higher chance of achieving goal blood pressure (64.6%) and receiving thiazide diuretics (68.1%) (adjusted p=0.002 and p<0.001, respectively). After returning to usual care after clinical pharmacy intervention, 22.2% of subjects had controlled blood pressure (P 0.001Managing hypertension with clinical pharmacy has reduced blood pressure. When clinical pharmacy management is discontinued, patient control is lost long-term